Asian Spectator


The Times

.

Sighting Dragons in the Field: An Exhibition of Dinosaur Fossils from Port Island and the Chinese Mainland

HONG KONG SAR – Media OutReach Newswire – 20 November 2026 – The opening ceremony of "Sighting Dragons in the Field: An Exhibition of Dinosaur Fossils from Port Island and the Chine...

Newly launched pattern design platform 'Space Tailor' helps pr...

SEOUL, South Korea, May 31, 2021 /PRNewswire-AsiaNet/ -- The digital printing market has been struggling recently due to the economic downturn and soaring inflation. Thus, some printing comp...

‘Scaling Hong Kong to the Nordics’ Concludes its Delegation Visit to Finland, Sweden and Denmark, Meeting Local Companies and Investors to Explore Business Opportunities in Nordic Markets

HONG KONG SAR - Media OutReach - 24 May 2022 - “Scaling Hong Kong to the Nordics”, co-organised by Cyberport and the Finnish Chamber of Commerce in Hong Kong (FinnCham Hong Kon...

The Institute of Brewing Distilling launches Essentials in B...

LONDON, March 3, 2022 /PRNewswire-AsiaNet/ -- The first on-demand course designed by the IBD for professionals working in supporting areas of a brewery, hospitality or beer loversThe Institu...

Make Celebrations Extraordinary: 1664 and CLOT Unveil the Next Chapter of the East-Meets-French Story in Asia

The latest partnership introduces limited-edition designs and curated experiences this festive season, bringing a new spirit of celebration to the regionHONG KONG SAR – Media OutReach...

Singapore Book Publishers Association presents Singapore Literature Book Bazaar 2022

SINGAPORE - Media OutReach - 10 March 2022 - To encourage appreciation of Singapore Literature amongst young and working adults. The Singapore Book Publishers Association (SBPA) is organis...

Chevron Apartments Pty Ltd Announce the Offering of Secured Lo...

MELBOURNE, Australia, Dec. 1, 2021 /PRNewswire-AsiaNet/ -- Chevron Apartments Pty Ltd ACN 620 459 118 is seeking to raise a total of A$231,110,414 in funds by the issue of loan notes, accord...

Largest Single Investment Into Disability Business Inclusion A...

LONDON, Jan. 29, 2021 /PRNewswire-AsiaNet/ -- - The Nippon Foundation is announced as the Global Impact Partner of The Valuable 500, the largest global network of CEOs committed to disabilit...

Promperú's Peru Trade Office Supports Expansion of Peruvian Agri-Food Export to Thailand

Thailand is the third biggest market for Peruvian agri-food exports in South-East AsiaPromperú will be relocating its trade office for South-East Asia to Bangkok after fou...

Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Denileukin Diftitox (Genetic Recombinant)

Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Denileukin Diftitox (Genetic Recombinant)

TOKYO, Mar 26, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has submitted in Japan a marketing authorization application of the anticancer agent denileukin diftitox (genetic recombinant) (generic name, development code: E7777) for relapsed or refractory Cutaneous T-cell Lymphoma (CTCL) and Peripheral T-cell Lymphoma (PTCL).

This application is based on data from a multicenter, open-label, single-arm Phase II clinical study (study 205) conducted in Japan for patients with relapsed or refractory CTCL or PTCL to evaluate the efficacy and safety of this agent.

This study achieved the primary endpoint and exceeded a predetermined threshold with statistical significance: the objective response rate (ORR) of CTCL and PTCL patients in total (n=36) was 36.1% (95% confidence interval (CI): 20.8-53.8). The ORRs of each subtype were 31.6% (95% CI:12.6-56.6) for CTCL (n=19) and 41.2% (95%CI: 18.4-67.1) for PTCL (n=17).

The five most frequent adverse events observed in this study were increased aspartate aminotransferase (AST) (89.2%), increased alanine aminotransferase (ALT) (86.5%), hypoalbuminaemia (70.3%), lymphopenia (70.3%), and pyrexia (51.4%).

Denileukin diftitox (genetic recombinant) is a fusion protein of the receptor-binding portion of interleukin-2 (IL-2) and diphtheria toxin that specifically binds to the IL-2 receptor on the surface of tumoral lymphocyte. The antitumor effect of denileukin diftitox depends on the intracellular delivery of diphtheria toxin which inhibits protein synthesis and induces cell death. The agent has been evaluated as a drug with high medical need by the "Study Group for Unapproved Drugs/Off-Label Drugs for High Medical Needs"(1), and Eisai has been requested to develop it by the Ministry of Health, Labour and Welfare.

Eisai positions oncology as a key franchise area and aims to create innovative drugs that act towards curing cancer. Eisai aims to make continuous efforts to meet the diversified needs of and increase the benefits provided to patients with cancer, their families, and healthcare professionals.

(1) The Study Group set up within the Ministry of Health, Labour and Welfare with the purpose of contributing to enhancing the development of drugs and indications that have not been approved in Japan (unapproved drugs/off-label drugs) by pharmaceutical companies. In addition to evaluating the medical needs of unapproved drugs/off-label drugs, their responsibilities include evaluating the applicability of the drug to an Application with Public Knowledge, and the adequacy of additional clinical studies that need to be conducted for filing applications for approval, and so on.

About Eisai

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.

In its medium-term business plan EWAY2025, Eisai is aiming to become a "Medico Societal Innovator" (a company that changes society through creating medicines and providing solutions), and is working on establishment of ecosystem platform business utilizing various data such as a large amount of clinical data, experiences, and know-how.

For more information about Eisai Co., Ltd., please visit https://www.eisai.co.jp.

Contact:Media Inquiries:
Public Relations Department
Eisai Co., Ltd. 
+81-(0)3-3817-5120

Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com

Authors: ACN Newswire - Press Releases

Read more //?#

Magazine

What to Consider Before Choosing a Cardboard Box Manufacturer

Start With the Packaging Purpose The right packaging begins with a clear understanding of what the box needs to do. A cardboard box manufacturer can help translate requirements such as product prot...

Why Emotional Battles Drain Your Wealth During Separation

Navigating a marriage ending is fundamentally a structural transition, not just an emotional event. When you approach separation with a clear roadmap, you protect your long term financial stability ...

How Long Does Botox Really Last? A Realistic Timeline

Someone might notice a line between their eyebrows getting deeper after a stressful week, or catch their forehead creasing in a video call in a way it did not before. It is a small observation, easy...

hacklink esim senegalzlibraryzlibraryuk casinos not on gamstophttps://www.capitolcitycinema.org/grandpashabet girişStreamEastCrackStreamscialis 20 mg fiyathttps://elektroniksigarakeyfi.net/marka/voopoo/taraftarium24taraftarium24extrabetgrandpashabet giriş